Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Supporting the implementation of the Cancer Mission · HORIZON-RIA · Needs partners
What this call funds
This call funds early-stage clinical research to test new precision cancer medicines or combined treatment approaches for people with rare or very rare cancers. It supports finishing lab-based drug validation and running first-in-human phase 1 clinical trials to check safety and early effectiveness. The goal is to give patients faster access to promising treatments and give health authorities the evidence needed to consider wider use.
biotechnology · pharmaceuticals · medical devices · diagnostics · genomics · public health
Who wins this
A multidisciplinary consortium of clinical researchers, hospitals, and biotech innovators running or preparing first-in-human phase 1 trials for rare cancer treatments, working closely with patients and regulators.
Could you win this call?
We read your site to see what you build.
The call in detail
- Indicative grant size
- €7M–€9M
- Funding model
- Lump sum — paid per completed work package, no financial reporting of actual costs
- Submission
- Single-stage submission (full proposal at once)
- Type of action
- HORIZON Research and Innovation Actions
- Partners
- Required. The call asks for a consortium — a group applying together, typically 3+ organisations from 3+ countries.
- Also required
- Applicants must provide proof of regulatory advice on clinical trial design and include detailed clinical study information in a dedicated annex; successful proposals must join the EU Cancer Mission 'Diagnosis and treatment' cluster and budget for networking/joint activities.
- Eligible countries (45)
- Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, Switzerland, United Kingdom, IL, TR, UA, RS, MK, ME, AL, BA, XK, GE, AM, MD, TN, NZ
Read the full conditions from the official call ›
General conditions 1. Admissibility conditions: Proposal page limit and layout described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout: described in Part B of the Application Form available in the Submission System. 2. Eligible countries described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide. 3. Other Eligibility Conditions described in Annex B of the Work Programme General Annexes. 4. Financial and operational capacity and exclusion described in Annex C of the Work Programme General Annexes. 5a. Evaluation and award: Award criteria, scoring and thresholds described in Annex D of the Work Programme General Annexes. 5b. Evaluation and award: Submission and evaluation processes The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12. described in Annex F of the Work Programme General Annexes and the Online Manual. 5c. Evaluation and award: Indicative timeline for evaluation and grant agreement described in Annex F of the Work Programme General Annexes. 6. Legal and financial set-up of the grants Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf ]]. The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5. described in Annex G of the Work Programme General Annexes. Specific conditions described in the specific topic of the Work Programme
Who has won calls like this
Organisations that most often win this call family · 71 past winners